Altimmune, Inc. (ALT) Insider Trading Activity

NASDAQ$3.86
Market Cap
$340.67M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
239 of 882
Rank in Industry
134 of 505

ALT Insider Trading Activity

ALT Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$273,619
9
100
Sells
$0
0
0

Related Transactions

Durso Jerome Benedictdirector
2
$122,359
0
$0
$122,359
WEAVER GREGORY LChief Financial Officer
2
$69,696
0
$0
$69,696
GILL JOHNdirector
1
$51,250
0
$0
$51,250
Pisano Waynedirector
1
$20,410
0
$0
$20,410
Sohn Catherine A.director
2
$7,902
0
$0
$7,902
Jorkasky Dianedirector
1
$2,003
0
$0
$2,003

About Altimmune, Inc.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Insider Activity of Altimmune, Inc.

Over the last 12 months, insiders at Altimmune, Inc. have bought $273,619 and sold $0 worth of Altimmune, Inc. stock.

On average, over the past 5 years, insiders at Altimmune, Inc. have bought $137,217 and sold $715,422 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Durso Jerome Benedict (director) — $122,359. WEAVER GREGORY L (Chief Financial Officer) — $69,696. GILL JOHN (director) — $51,250.

The last purchase of 20,000 shares for transaction amount of $70,790 was made by Durso Jerome Benedict (President and CEO) on 2026‑03‑06.

List of Insider Buy and Sell Transactions, Altimmune, Inc.

2026-03-06PurchaseDurso Jerome BenedictPresident and CEO
20,000
0.0227%
$3.54
$70,790
+12.66%
2026-03-06PurchaseWEAVER GREGORY LChief Financial Officer
5,000
0.0057%
$3.54
$17,700
+12.66%
2026-01-08PurchasePisano Waynedirector
5,000
0.0057%
$4.08
$20,410
+10.78%
2026-01-05PurchaseSohn Catherine A.director
500
0.0007%
$4.24
$2,118
+9.90%
2025-12-29PurchaseJorkasky Dianedirector
527
0.0006%
$3.80
$2,003
+21.20%
2025-12-23PurchaseGILL JOHNdirector
12,500
0.014%
$4.10
$51,250
+9.50%
2025-12-22PurchaseDurso Jerome Benedictdirector
12,500
0.0141%
$4.13
$51,569
+4.95%
2025-03-17PurchaseSohn Catherine A.director
1,000
0.0013%
$5.78
$5,785
-28.77%
2025-03-13PurchaseWEAVER GREGORY LChief Financial Officer
10,000
0.013%
$5.20
$51,996
-18.08%
2024-08-19SaleDrutz Daviddirector
16,011
0.0206%
$6.90
$110,547
-15.98%
2023-08-15PurchaseDrutz Daviddirector
300
0.0006%
$2.88
$863
+145.20%
2023-03-24PurchaseEisenstadt Richard IChief Financial Officer
10,000
0.0213%
$4.31
$43,140
-5.32%
2023-03-23PurchaseHarris Matthew ScottChief Medical Officer
10,000
0.0215%
$4.22
$42,200
-2.39%
2023-03-23PurchaseDrutz Daviddirector
9,000
0.0195%
$4.27
$38,430
-2.39%
2022-12-22SalePisano Waynedirector
20,000
0.0383%
$15.01
$300,268
-73.88%
2022-08-30SaleGarg Vipin KPresident and CEO
20,000
0.0429%
$20.02
$400,322
-47.31%
2022-08-12SaleGarg Vipin KPresident and CEO
15,000
0.0264%
$15.06
$225,890
-39.92%
2022-08-12SaleGILL JOHNdirector
2,714
0.0048%
$15.00
$40,710
-39.92%
2022-07-01SaleRoberts M ScotChief Scientific Officer
10,182
0.022%
$12.00
$122,184
+0.62%
2022-06-29SaleRoberts M ScotChief Scientific Officer
5,462
0.0117%
$12.00
$65,546
-3.74%
Total: 157
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Durso Jerome BenedictPresident and CEO
32500
0.0368%
$125,450.0020
WEAVER GREGORY LChief Financial Officer
28078
0.0318%
$108,381.0820
Pisano Waynedirector
13498
0.0153%
$52,102.2822
<0.0001%
GILL JOHNdirector
12500
0.0142%
$48,250.0022
<0.0001%
Sohn Catherine A.director
1500
0.0017%
$5,790.0020
Jorkasky Dianedirector
527
0.0006%
$2,034.2211
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.10 percent owner
6626403
7.5081%
$25.58M13
EVNIN LUKE10 percent owner
6347614
7.1922%
$24.5M20
MPM BIOVENTURES III LLC10 percent owner
6347614
7.1922%
$24.5M20
Venrock Healthcare Capital Partners III, L.P.10 percent owner
4500000
5.0987%
$17.37M40
+64.5%
VELOCITY PHARMACEUTICAL HOLDINGS LLC10 percent owner
1687250
1.9117%
$6.51M02
SCHAFFER DERACE Ldirector
589453
0.6679%
$2.28M415
<0.0001%
KINLEY MATTHEW P
541000
0.613%
$2.09M110
WRIGHT DAVID PPresident and CEO
399500
0.4527%
$1.54M80
PAPPAJOHN JOHNdirector
394044
0.4465%
$1.52M153
Enright WilliamPresident and CEO
365839
0.4145%
$1.41M10
<0.0001%
HEALTHCARE VENTURES VII LP10 percent owner
250000
0.2833%
$965,000.0010
Garg Vipin KPresident and CEO
236797
0.2683%
$914,036.4212
RICHMAN ERIC Idirector
176822
0.2003%
$682,532.9223
Riddle Valerie DSVP, Medical Director
44436
0.0503%
$171,522.9603
Drutz Daviddirector
41958
0.0475%
$161,957.8861
+43.65%
Harris Matthew ScottChief Medical Officer
33311
0.0377%
$128,580.4612
<0.0001%
SAYARE MITCHELdirector
32650
0.037%
$126,029.0020
<0.0001%
CHANG LINDA LSVP, CFO & Secretary
30000
0.034%
$115,800.0011
St Peter Stevendirector
25000
0.0283%
$96,500.0010
Eisenstadt Richard IChief Financial Officer
22010
0.0249%
$84,958.6010
<0.0001%
Runge Jeffrey W.director
20000
0.0227%
$77,200.0020
FUERST THOMAS RICHARDSVP, Chief Scientific Officer
15000
0.017%
$57,900.0020
Karp Jordan PSVP, General Counsel
10000
0.0113%
$38,600.0010
Schafer Klausdirector
8900
0.0101%
$34,354.0011
+5.5%
Hodges Philipdirector
8731
0.0099%
$33,701.6603
Roberts M ScotChief Scientific Officer
8305
0.0094%
$32,057.3013
<0.0001%
Price KevinPresident-Pharmathene UK, Ltd.
2500
0.0028%
$9,650.0010
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$26,922,905
100
5.55%
$307.19M
$5,960,789
91
-7.17%
$373.24M
$69,151,774
71
24.96%
$337.81M
Altimmune, Inc.
(ALT)
$24,384,691
42
-30.27%
$340.67M
$16,169,789
40
7.44%
$345.84M
$64,487,106
32
-22.92%
$306.92M
$54,828,550
26
-13.88%
$369.67M
$1,447,973
17
13.95%
$330.2M
$65,355,913
13
-3.42%
$358.16M
$8,069,667
13
-13.57%
$355.29M
$10,143,329
12
11.84%
$323.87M
$81,667,942
12
-57.54%
$381.94M
$112,952,085
11
-19.19%
$367.23M
$603,645
8
57.40%
$354.14M
$13,043,783
8
732.82%
$319.6M
$17,675,244
7
92.20%
$308.31M
$1,346,998
7
25.06%
$322.05M
$2,720,023
3
-11.76%
$357.35M
$4,888,000
3
-20.50%
$321.61M

ALT Institutional Investors: Active Positions

Increased Positions124+89.86%17M+41.72%
Decreased Positions53-38.41%4M-9.55%
New Positions48New3MNew
Sold Out Positions23Sold Out1MSold Out
Total Postitions209+51.45%55M+32.17%

ALT Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$22,371.006.13%6.37M+1M+23.35%2025-09-30
Blackrock, Inc.$22,370.006.13%6.37M+699+0.01%2025-09-30
State Street Corp$12,640.003.46%3.6M+847,617+30.78%2025-09-30
Tang Capital Management Llc$7,481.002.05%2.13M-618,693-22.5%2025-09-30
Geode Capital Management, Llc$7,081.001.94%2.02M+82,505+4.26%2025-09-30
Two Sigma Investments, Lp$7,009.001.92%2M+2M+356.65%2025-09-30
Morgan Stanley$5,234.001.43%1.49M+655,642+78.48%2025-09-30
Two Sigma Advisers, Lp$5,014.001.37%1.43M+1M+1,005.57%2025-09-30
Susquehanna International Group, Llp$4,823.001.32%1.37M-245,565-15.16%2025-09-30
Citadel Advisors Llc$4,500.001.23%1.28M+758,553+144.91%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.